Quick Answer
Dermata Therapeutics, Inc. reported R&D Expense of $2.93 million for fiscal year 2025.
Dermata Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $2.93M | -64.3% |
| 2024 | $8.20M | +101.6% |
| 2023 | $4.07M | -28.0% |
| 2022 | $5.65M | +63.4% |
| 2021 | $3.46M | +115.2% |
| 2020 | $1.61M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $504.4K | -79.0% | -18.4% |
| June 30, 2025 | $617.8K | -69.2% | -51.8% |
| March 31, 2025 | $1.28M | -20.0% | -46.6% |
| September 30, 2024 | $2.40M | +165.9% | +19.5% |
| June 30, 2024 | $2.01M | +139.5% | +25.5% |
| March 31, 2024 | $1.60M | +34.2% | +77.3% |
| September 30, 2023 | $903.0K | -41.9% | +7.6% |
| June 30, 2023 | $838.9K | -48.0% | -29.7% |
- Dermata Therapeutics, Inc. showed a decrease of -64.3% in R&D Expense compared to the prior fiscal year.
- Over the 2020–2025 period, Dermata Therapeutics, Inc.’s r&d expense has grown by 82.2% (from $1.61 million to $2.93 million).
- The most recent figure is from Dermata Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: